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Abstract
Background: Stillbirth is a devastating pregnancy outcome that has a profound and lasting impact on women and
families. Globally, there are over 2.6 million stillbirths annually and progress in reducing these deaths has been slow.
Maternal perception of decreased fetal movements (DFM) is strongly associated with stillbirth. However, maternal
awareness of DFM and clinical management of women reporting DFM is often suboptimal. The My Baby’s
Movements trial aims to evaluate an intervention package for maternity services including a mobile phone
application for women and clinician education (MBM intervention) in reducing late gestation stillbirth rates.
Methods/design: This is a stepped wedge cluster randomised controlled trial with sequential introduction of the
MBM intervention to 8 groups of 3–5 hospitals at four-monthly intervals over 3 years.
The target population is women with a singleton pregnancy, without lethal fetal abnormality, attending for
antenatal care and clinicians providing maternity care at 26 maternity services in Australia and New Zealand. The
primary outcome is stillbirth from 28 weeks’ gestation. Secondary outcomes address: a) neonatal morbidity and
mortality; b) maternal psychosocial outcomes and health-seeking behaviour; c) health services utilisation; d)
women’s and clinicians’ knowledge of fetal movements; and e) cost. 256,700 births (average of 3170 per hospital)
will detect a 30% reduction in stillbirth rates from 3/1000 births to 2/1000 births, assuming a significance level of
5%. Analysis will utilise generalised linear mixed models.
Discussion: Maternal perception of DFM is a marker of an at-risk pregnancy and commonly precedes a stillbirth.
MBM offers a simple, inexpensive resource to reduce the number of stillborn babies, and families suffering the
distressing consequences of such a loss. This large pragmatic trial will provide evidence on benefits and potential
harms of raising awareness of DFM using a mobile phone app.
Trial registration: ACTRN12614000291684. Registered 19 March 2014.
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Background
Stillbirth has profound and long-lasting adverse psycho-
social and economic impacts on women and families,
and also on health systems and society [1]. In 2015, an
estimated 2.6 million stillbirths occurred globally with
rates showing little or no decline [2]. While the majority
of stillbirths occur in low and middle income countries,
[2] high-income countries (HIC) still have substantial
numbers of preventable stillbirths, [3] particularly be-
yond 28 weeks’ gestation, where survival for those born
alive approaches 100% [4].
In HIC settings, stillbirth is now over twenty times
more common than Sudden Unexpected Deaths in In-
fancy [5] where focussed prevention strategies, including
awareness campaigns, have reduced these deaths by over
80% [6]. The scale of the hidden tragedy of stillbirth was
the impetus for The Lancet to publish the 2011 [7–11]
and 2016 stillbirths series [1–3, 12, 13] with a global call
to action [12] to reduce preventable stillbirths focussing
on births of 28 weeks’ or more gestation (late gestation).
The Lancet’s 2016 series showed wide variation in late
gestation stillbirth rates across 49 HIC ranging from 1.7/
1000 to 8.8/1000 births, [3] highlighting the potential to
further reduce stillbirth rates in such settings. In this
series, New Zealand and Australia ranked 10th and 15th
with rates of 2.3 and 2.7/1000 births respectively, indi-
cating the potential for focussed attention to reduce pre-
ventable stillbirth [3].
In Australia and New Zealand, using the standard def-
inition of stillbirth of 20 weeks or 400 g birthweight, the
most recent annual data shows 2107 (6.7/1000) in
Australia, [4] and 457 (7.5/1000) in New Zealand [14];
equating to seven deaths every day. Women who are so-
cially disdavantaged have around twice the risk of still-
birth [3]. Ethnicity is also associated with stillbirth;
Indigenous Australian women, [4] Pacific Islanders in
New Zealand [14] and South Asian born women [15]
have around twice the risk.
The challenge of stillbirth prevention
With improvements in intrapartum care in HIC settings,
the majority of stillbirths now occur in the antepartum
period [8]. The on-going risk of stillbirth increases each
week towards the end of pregnancy [16]. In addtition,
maternal and fetal factors which increase the risk in-
clude maternal overweight and obesity, smoking in preg-
nancy, age 35 years or more, fetal growth restriction, and
previous stillbirth [17]. In the absence of a reliable
screening test for stillbirth, early identificaiton of risk
factors combined with appropriate monitoring and early
birth, when indicated, is the mainstay of management to
reduce late gestation stillbirth [3].
DFM is a marker of an at-risk pregnancy [18, 19].
DFM is thought to be an adaptive response to acute or
chronic placental dysfunction whereby the fetus reduces
gross movement to conserve blood flow for the vital or-
gans [19]. Women who experience DFM have a four-
fold increased risk of stillbirth [19–21] and double the
risk of fetal growth restriction [22, 23]. DFM is also as-
sociated with other serious adverse outcomes including
feto-maternal haemorrhage, low birth weight, neonatal
death and neurodevelopmental disability [24]. Clinical
audits into substandard care show that around 20–30%
of stillbirths may have been avoided through better care,
[8] with deficiencies in care around detection and man-
agement of women with decreased/reduced fetal move-
ments a common finding [25–27].
DFM and the evidence for raising awareness
No universally agreed definition of DFM currently exists
[28] and none are sufficiently robust as a screening tool
for adverse pregnancy outcomes [29]. Maternal percep-
tion of DFM is more effective in detecting at-risk preg-
nancies than any threshold based on maternal count of
fetal movements [18]. Many stillbirths are preceded by
perceived DFM for a number of days [19, 30] and
mothers who delay reporting DFM increases the risk of
stillbirth [31].
A systematic revew of interventions to raise awareness
and improve outcomes for women with DFM showed no
clear beneift [32]. Fetal movement counting (where
women record the number of movements using a kick
chart) has been proposed as an intervention to reduce
stillbirth rates through increasing maternal awareness of
DFM. However, the Cochrane systematic review on fetal
movement (FM) counting showed no reduction in still-
births [33]. In the largest trial of kick counting, [34]
while no reduction was shown in stillbirth rates, the
overall late gestation stillbirth rate fell during the study
period from 4 per 1000 to 2.8 per 1000 births. It was
postulated that this reduction was due to an increased
awareness and vigilance of DFM [28]. In a non-
randomised quality improvement study across 14 hospi-
tals in Norway [35, 36] a similar reduction was shown
for a package of care to raise awareness of DFM (with
optional kick counting) and a standardised protocol for
clinical management. Importantly, in the Norwegian
study women with DFM presented for care earlier dur-
ing the intervention period. A more recent indiviual par-
ticipant randomised controlled trial [37] showed that
kick counting increased antenatal detection of FGR.
While the trial was not designed to detect a difference in
stillbirth rates, no difference was shown in the propor-
tion of women presenting with DFM, induction rates,
maternal concern about the baby [38] or maternal fetal
attachment [22]. Recruitment into this trial was low (<
20% of all eligible women), suggesting that kick counting
may not be widely acceptable to women. The recent
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AFFIRM trial in the UK [39] showed that a package of
care to improve awareness and management of women
with DFM resulted in an increase in induction of labour,
caesarean section and neonatal admission to special care
nursery. A non-statistically significant reduction in still-
birth rates of 10% was shown. The trial investigators
concluded that changes in practice around DFM should
await the results of ongoing trials.
Planned early birth to avoid stillbirth may result in in-
creased maternal and neonatal adverse outcomes. While
the risks of preterm birth are well understood, recent
sudies have shown early-term birth (at 37 and 38 weeks)
is associated with adverse neonatal and childhood out-
comes [40]. Therefore, the risk of stillbirth must be care-
fully weighed against the risks associated with early birth
at a given gestational age [41].
Practices in Australia and New Zealand
A survey of obstetricians in Australia and New Zealand
on care for women with DFM showed the majority
agreed that maternal concern was the most valid defin-
ition of DFM [42]. However, low awareness and know-
ledge of the importance of DFM, and suboptimal
practice in response to women’s reports of DFM, is evi-
dent [24]. Incorrect beliefs are common place, such as
that a decrease in movements towards the end of preg-
nancy is normal [43]. Women often report not receiving
information about DFM and many delay seeking care
when DFM occurs [44]. Women who do receive infor-
mation are more likely to know what to do when con-
cerned [45]. To enhance consistency and quality of care
for women presenting with DFM, a clinical practice
guideline on DFM has been developed [24] with an ac-
companying brochure for women, which has been trans-
lated into 19 languages [46]. An e-learning program for
clinicians has also been developed [47].
Methods/design
Aim
The aim of the MBM trial is to evaluate the effectiveness
of a mobile phone application for women combined with
an educational program for clinicians (MBM interven-
tion) in reducing late gestation stillbirth rates.
The My Baby’s Movements mobile phone program
mHealth is increasingly a feature of the healthcare land-
scape and mobile phone applications (apps) are widely
used by pregnant women, who rate them as helpful for
providing general reassurance and information about
fetal development [48, 49]. Although the effects of mo-
bile phone apps on pregnancy outcomes are yet to be
established, [50] their reach and acceptability levels
mean that this form of technology holds much promise
for the delivery of appropriately tailored evidence-based
information.
The My Baby’s Movement mobile phone program
(MBM phone program) consists of a mobile phone app
(Fig. 1), or a short message service (SMS) based program
for women without access to a smartphone. The aim of
the MBM phone program is to provide quality informa-
tion about fetal movements to pregnant women, and to
encourage early reporting if a decrease in movement oc-
curs. A digital innovation company was contracted to
create the MBM phone program to ensure an end-
product that was accessible, engaging and interactive for
users. Development included user engagement involving
Fig. 1 My Baby’s Movement application. Display of MBM app
opening page
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focus groups and interviews with pregnant women and a
focus group with clinicians was conducted at the Mater
Mothers’ Hospital (MMH). The MMH is a large tertiary
service in Queensland, Australia and was chosen for
convenience, [51] as it co-located with the main coord-
inating centre (Mater Research Institute, University of
Queensland) and runs a specialised service for Aborigi-
nal and Torres Strait Islander women, enabling ready ac-
cess to potential participants for this work. Key
considerations in development of the MBM program in-
cluded acceptability and expectations of content and its
delivery, cultural appropriateness, health literacy, and
patient beliefs and misperceptions. All communications
via the MBM app and SMS were designed to be deliv-
ered in a supportive and non-alarmist manner. Consult-
ation with Aboriginal and Torres Strait Islander
researchers, clinicians and community representatives
provided essential feedback and ultimately a fetal move-
ment information brochure tailored to Indigenous
women and modifications to the MBM app including
minor wording changes and a visual ‘theme’ option that
incorporated Indigenous artwork.
The MBM app sends an alert to prompt the woman’s
awareness of her baby’s movements at a time and fre-
quency of her choice, from 28 week’s gestation until
birth. If concerned, she is encouraged to contact her
health care provider without delay. The app also pro-
vides a ‘movement counter’ option where the woman
can record the number of movements she feels over a
two-hour period, and a strength recorder option where
she can record the strength of her baby’s movements if
she wishes. This information is stored in the woman’s
app diary for her review at any time. The alternative
SMS program sends a series of messages to the woman
on a weekly basis from 28 to 33 + 6 weeks’ gestation, and
a twice-weekly basis from 34 to 42 weeks’ gestation. The
messages include facts about fetal movements and a
prompt to contact her healthcare provider if concerned
about her baby’s movements. This is a one-way messa-
ging system with no option for women to seek further
advice or care via the MBM SMS. Accordingly, all SMS
texts included the words ‘Do not reply’.
Hypothesis
The primary hypothesis is that the MBM intervention
will result in a reduction in stillbirth rates at 28 weeks’
or more gestation in women with a singleton pregnancy
from 3/1000 to 2/1000. The baseline stillbirth rate is
based on outcome data from the participating hospitals.
Outcome measures
Primary endpoint
Stillbirth rates 28 weeks’ or more gestation in women
with a singleton pregnancy.
Secondary endpoints are as follows
a) Newborn outcomes: a composite measure of
adverse outcome defined as one or more of the
following - stillbirth, hypoxic ischemic
encephalopathy, neonatal seizures; Meconium
Aspiration Syndrome; stillbirths (20 weeks’ gestation
or more); gestation at birth; birthweight; FGR at
birth; Apgar Score < 7 at 5 min; umbilical artery pH
< 7.0; intubation and ventilation at birth; use of
mechanical ventilation; neonatal death (death of a
live born infant regardless of gestation or
birthweight); neonatal death at 28 weeks’ or more
gestation.
b) Obstetric outcomes: induction of labour; caesarean
section, intrapartum and postpartum infection;
postpartum haemorrhage; maternal admission to
intensive care.
c) Health service utilisation measures: episodes of
women presenting with DFM at > 28 weeks’
gestation; antenatal admission to hospital for DFM;
antenatal ultrasound; duration of neonatal intensive
care, special care nursery and total hospital stay;
and maternal length of hospital stay.
d) Woman’s psychosocial outcomes and health seeking
behaviour and acceptability: Maternal reporting of
DFM delayed by > 24 h; acceptability of information
on DFM and of MBM; women’s and clinicians’
knowledge of FM; maternal-fetal attachment (the
Prenatal Attachment Inventory (PAI)) [52]; maternal
pregnancy-related worries and concerns (the Cam-
bridge Worry Scale Score [53];) anxiety (State-Trait
Anxiety Index [54]); the Edinburgh Postnatal Depres-
sion Scale (EPDS) [55];; quality of life (QoL)(AQol8D)
[56]; and health status (SF36, 57] at the end of preg-
nancy (or birth) at 6 months postpartum.
Cost-effectiveness
A within trial cost-effectiveness analysis has also been
designed to identify the incremental cost-effectiveness
ratio of the mobile phone app and clinical education
intervention relative to standard care. All costs to the
health care system will be included, and the outcome of
interest is the change in number of stillbirths.
Patient and public involvement statement
The My Baby’s Movements trial is an endorsed trial of the
Perinatal Society of Australia and New Zealand (PSANZ)
Interdisciplinary Maternal and Perinatal Australasian Col-
laborative Trials (IMPACT) Network. An integral part of
the development of IMPACT Network endorsed trials is
consultation with consumers through consultation with
the PSANZ Consumer Advisory Group and feedback at
open forums. The voice of parents and the public was fur-
ther incorporated into the MBM trial development
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through partnership with the Stillbirth Foundation
Australia and through focus groups and one-to-one inter-
views as part of the MBM app development phase. Con-
sultation with Aboriginal women was enabled through an
Indigenous stillbirth advisory group established specifically
for the MRI-UQ stillbirth research program.
Study design
This is a cluster-randomised, stepped-wedge design
trial wherein maternity facilities are randomised in
groupings (or clusters). All units will implement the
MBM intervention at randomly-assigned points during
the trial; these time points are the so-called “step” of
the stepped-wedge design. The MBM trial design pro-
poses sequential introduction of the intervention into
eight groups of 3–5 hospitals at four-monthly inter-
vals over a total of 3 years (Fig. 2).
Nested studies are planned including: cross sectional
surveys to determine acceptability of information and
knowledge on DFM; women’s use of MBM and per-
ceptions of acceptability; clinical audits of presenta-
tions with DFM to determine changes in patterns of
reporting of DFM and management; and focus groups
studies to determine the acceptability of the interven-
tion to women and clinicians.
Study sites
Twenty-six maternity hospitals in Australia and New
Zealand (ANZ).
Study population
Inclusion criteria
Women with a singleton pregnancy attending for ante-
natal care; and midwives and doctors providing mater-
nity care at the participating hospitals.
Exclusion criteria
Women with a lethal fetal congenital abnormality (CA).
Lethal fetal congenital abnormalities are defined as
those that are unequivocally lethal.
Sample size
The trial will include 26 hospitals in ANZ with an aver-
age of 3170 singleton births per year (range: 1400, 7000)
giving 256,770 total births over 3 years. With a stillbirth
rate 28 weeks’ or more gestation of 3 per 1000 we would
expect (without the MBM intervention) 770 stillbirths
(> 28 weeks), with 10% due to lethal congenital abnor-
malities where the intervention is unlikely to have an ef-
fect, leaving 693 stillbirths. MBM is hypothesised to
reduce the rate to 2 per 1000, which is considered an
achievable benchmark for a high income country and
was the effect size observed in the Norwegian study [36].
We calculated statistical power using the methodology
for stepped wedge designs proposed in Hussey and
Hughes [57]. The calculation based on equations (#7)
and (#8) assumes: significance level of 5%; analysis by
generalised linear mixed model; births equally distrib-
uted across hospital groupings; baseline stillbirth rate
0.3%; intervention stillbirth rate 0.2%; an intra-class cor-
relation (ICC) = 0.005 [58]. The ICC reflects the fact that
for large clusters (n = 3170), the ICC is small. We
propose sequential introduction of the intervention into
eight groups of 3–5 hospitals at four-month intervals;
over a total of 3 years (see Fig. 2). This will give 89%
power to detect a 30% relative risk reduction in stillbirth
rates (from 3/1000 to 2/1000), 85% power to detect a
25% reduction, and 80% power to for a 15% reduction.
The trial methods have been harmonised with that of in
the AFFIRM trial [39]. Combining data from the two tri-
als, with an estimated 700,000 births, would give 89%
power to detect a 10% decrease in stillbirth rates.
Trial procedure
Randomisation and allocation
Clusters are assigned to the timing of the intervention
(control and interventions periods) using a computer-
generated random number table by the trial biostatistician
(Michael Coory) who is not to be involved in the clinical
aspects of the study. Randomisation is stratified by hos-
pital size (< 3000 and > 3000 births/ year) and proximity
to each other (groups of hospitals which are in close prox-
imity to each other will be treated as strata).
Fig. 2 My Baby’s Movements stepped-wedge design. Stepped-
wedged cluster design
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Study group management
Control Period Standard care: Standard care across
these maternity services usually includes provision of the
bi-national brochure to women [46] and management of
women according to the recommended guidelines [24].
Key recommendations include that all pregnant women
should receive information about what constitutes nor-
mal FM and advise that concerns for a decrease in
movements should be reported to a health care provider
without delay. Upon presentation for care, and exclusion
of fetal death, recommended clinical care includes a car-
diotocograph (CTG) to exclude imminent fetal demise
followed by a thorough examination and testing for ma-
ternal fetal haemorrhage. In the presence of risk factors
or concerns about fetal growth, an ultrasound scan
should be performed. Specific recommendations on tim-
ing of birth are not provided.
Intervention Period MBM: In addition to standard care
as provided in the control period, during the interven-
tion period all eligible women will be offered the use of
the MBM mobile phone app (or SMS messages for those
who do not have a smartphone). All maternity care staff
will be encouraged to complete an on-line DFM educa-
tional program, which educates and tests staff on the
clinical care pathways for women presenting with de-
creased fetal movements, as outlined in Fig. 3. All sites
receive a site visit from the CI team which includes pres-
entation to staff on management of women with DFM.
Eight weeks prior to implementation, a teleconference
is held with the MBM site team (usually made up of a
midwifery educator, obstetrician and research midwife)
and the MBM trial team to plan implementation, taking
into consideration local procedures. The site team will
be provided with an educational package about MBM
and management of women with DFM to use in ongoing
in-service education. One week prior to the commence-
ment of the intervention phase, a site visit by the MBM
trial team will be undertaken to present the trial and the
management of women with DFM to clinical staff.
To access the MBM mobile phone program, each
woman will be provided a unique Study ID generated
through a purpose-built database. Registration will be
undertaken by the staff at the maternity services. For
women using the MBM app, the Study ID will be
Fig. 3 Care pathway for women presenting with decreased fetal movements from 28 weeks’ gestation. Clinical care management algorithm for
women presenting with decreased fetal movements
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provided via SMS message on the day of registration or
at 27 weeks’ gestation (whichever comes last). This mes-
sage will include the woman’s unique MBM Study ID
and instructions on how and where to download the
MBM app. Once she has downloaded the app, the
woman can sign-in to the app using her mobile phone
number and unique MBM Study ID.
From 28 weeks’ gestation until birth the attending clin-
ician will be asked to remind women about the use of
MBM and reinforce the importance of being aware of
DFM and when and how to contact the hospital. If the
woman is found not to be currently registered in the
MBM database, this can be arranged at any visit, regard-
less of gestation.
After the birth, women who have used the MBM app
are given the option of completing a questionnaire em-
bedded within the app. This is a 12-question survey ask-
ing women to rate app satisfaction, usefulness, and
whether they would recommend MBM to others.
Data collection
Routinely collected electronic perinatal data: will be
accessed either through the health departments within
each jurisdiction or hospitals. Data items are as follows:
i) Maternal demographics and obstetric history; previ-
ous stillbirth, previous miscarriage, previous neonatal
death, previous FGR, previous preterm birth; maternal
age; ethnicity; country of birth; body mass index; alcohol
intake during pregnancy; smoking status at booking and
at 20 weeks’ gestation; illicit drug use; education level;
postcode; plurality; parity; Pre-existing major medical con-
ditions including hypertension, diabetes, mental health
and other.
ii) Pregnancy and birth outcomes; stillbirth, neonatal
death, hypoxic ischemic encephalopathy, neonatal sei-
zures; cause of neonatal death and stillbirth; gestation at
birth; birthweight; FGR at birth; major congenital abnor-
mality; Apgar Score < 7 at 5min; umbilical artery pH <
7.0; intubation and ventilation at birth; Meconium Aspir-
ation Syndrome; use of mechanical ventilation; neonatal
death; reason for admission to nursery; onset of labour;
mode of birth; major maternal pregnancy and birth com-
plications including APH, pre-eclampsia, gestational
hypertension, diabetes; maternal admission to intensive
care; antenatal diagnosis of FGR.
Additional data items are as follows:
a) Audit of presentations for DFM: will be undertaken
for two four-week periods prior to the commencement
of the control period and at 6 months after the start of
the intervention period using a purpose-built data col-
lection form. Data collected will include the duration of
maternal concern of DFM at the time of presentation,
investigations undertaken and outcome of clinical
assessment.
b) Surveys of women: will be undertaken over a four-
week period immediately before commencement of the
site education and again at 6 months after the start of
the intervention period. Women will be asked during a
routine antenatal visit at 35 weeks’ or more gestation or
up to one-week post-partum to complete a survey to
elicit psychosocial outcomes, knowledge and acceptabil-
ity of the DFM information. A follow-up survey will be
undertaken at 6 months postpartum by mail-out or by
email (depending on the woman’s preference), to deter-
mine psychosocial outcomes, quality of life, and health
services utilisation since discharge.
c) Acceptability of the MBM Tool: and factors that
might inhibit utilisation will be assessed using qualitative
methods. Four focus groups of 6–10 women, homoge-
neous for characteristics potentially associated with
poorer uptake (young age; low socioeconomic status; In-
digenous background) will be conducted towards the
end of the intervention period. In addition, two focus
groups of midwives and doctors will be undertaken to-
wards the end of the intervention period. An experi-
enced facilitator will use a semi-structured guide to elicit
views and fresh insights into the intervention. Focus
groups will be recorded and transcribed. Due to the im-
practicability of focus groups with multiple ethnic mi-
nority and other special needs groups, consultation and
key informant interviews (e.g. with those who provide
services for these specific population groups) will be
conducted at participating hospital sites to gain insights
into unique needs of specific populations served.
d) Economic evaluation: In addition to the routinely
collected perinatal data and the health service use ques-
tionnaire to be completed at the 6 months follow-up
time point, all Australian women completing the surveys
as well as all women experiencing a stillbirth will be
asked for consent to obtain their Medicare Benefits
Schedule (MBS) and Pharmaceutical Benefits Scheme
(PBS) claims data from the federal government via the
Department of Human Services.
Data management
Routinely collected perinatal data on singleton births over
the three-year study period will be submitted electronic-
ally to the coordinating centre at the Mater Research In-
stitute (MRI-UQ) by participating hospitals, or where
hospitals do not have electronic data collection at the site,
through the relevant health departments. Routine data will
be provided in de-identified format, ensuring patient
privacy and confidentiality. Where possible, data will be
gathered electronically and entered directly into the
purpose-built online database for the audit and surveys, in
the case of paper format electronic scanning format will
be utilised and entered by a member of the research team.
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Data harmonisation for routinely collected data
From the 26 different facilities we expect 16 different
system extracts. Due to the inconsistencies between sys-
tems, mapping will be undertaken to harmonise the
datasets. Processes will include field mapping of similar
fields and harmonisation of data points within these fields
by mapping with the use of ICD-10 coding [59] and agree-
ment by an expert panel consisting of investigators.
Linkage processes
Within the control period, datasets from women’s sur-
veys and audits will be linked to birth outcomes via de-
terministic linkage processes [60]. This process will be
completed via linking four common variables within
each data set; maternal date of birth, estimated date of
birth, hospital and timing of audit/survey. Within the
intervention period, the research midwife at each site
will enter re-identifiable data for eligible women into a
purpose-built online database as follows: hospital record
number, date of first antenatal visit, date of birth, and
estimated date of confinement. The database will gener-
ate a unique MBM ID for each woman for use on audit
forms and surveys. For women in the intervention
period, data from the woman’s surveys, use of the MBM
mobile phone program, and the DFM audits and birth
outcomes will be linked using the MBM ID number.
Analysis plan
Primary outcomes
To gain understanding of the population sample, initial
analyses will involve examination of baseline characteristics
of all women in the control and intervention periods, to
provide an indication of comparability of the groups and
identify potential confounders. Analyses of the primary out-
come will be modelled upon analyses undertaken in the
UK AFFIRM Trial [39]. To test the hypothesis that the
MBM package results in a reduction in stillbirth rates at 28
weeks’ or more gestation, the binary primary outcome of
stillbirth will be analysed via a generalised linear mixed
model. This model will include a random effect for facility
and fixed effects for the intervention implementation and
study time periods. For further understanding please refer
to the statistical analysis plan in the Additional file 1.
Intervention implementation (intention to treat group)
will be determined by grouping women who were exposed
to the intervention and those who were not, based upon
the stepped wedge design. As there are multiple levels of
intervention outlined within the study design, a further
subset analysis will be undertaken utilising app data from
women that utilised the MBM app. Utilisation of the
MBM app will be determined as women who not only
downloaded the app but accessed multiple pages of the
app across multiple time periods. Baseline characteristics
and similar analyses to the primary outcome analysis will
be conducted for this group, along with time series
analyses to understand specific app usage, stratified by
gestation and demographical variables. Mixed model re-
gression will be utilised to determine the differences in
outcomes for women who received the MBM SMS pro-
gram (non-smart phone users) and their birth outcomes.
Secondary Outcomes
Analysis of the secondary outcomes, will provide further
understanding of the impact of the MBM package on
birth and neonatal outcomes. Data will be analysed by
generalised linear mixed models to identify the estimated
adjusted odds ratio and 95% confidence interval for each
of the birth outcomes and adverse neonatal outcomes
identified in the aims. Outcomes measured on a continu-
ous scale will be analysed in a normal linear mixed model.
To determine the overall effectiveness of the intervention
on secondary outcomes, analysis will involve comparison
of the data points in the control section of the wedge with
those in the intervention section, [61] adjusting for poten-
tial confounders, including maternal age, congenital ab-
normalities and gestational age etc.
Economic evaluation
The incremental cost effectiveness ratio (ICER) for the
MBM intervention (i.e. the additional cost of an add-
itional stillbirth avoided) will be calculated from trial
data. Costs will include in-hospital and out-of-hospital
service use (including scans and tests) and prescription
medication use for the mother and baby. Hospital costs
will be derived from Australian Refined Diagnosis Re-
lated Groups (AR-DRG) cost weights for any maternal
or neonatal admission, out of hospital costs will be de-
rived directly from the MBS and PBS data. The primary
outcome of interest will be avoided stillbirth. A general-
ized linear mixed model will be utilised to compare total
costs per birth in the intervention and control groups.
The difference in the ICER between socioeconomic
groups will also be compared. Additionally, maternal
quality of life (QoL) will be measured using the AQoL8D
[56] and health status using SF-36 [62]. The number of
scans, caesarean sections, early inductions of labour and
admissions to Neonatal Intensive Care Unit or Special
Care Nursery will also be compared between interven-
tion and control groups.
Qualitative data
Thematic analysis will be applied to the qualitative data
collected throughout the study. Interviews will be
recorded, or detailed notes will be taken at each quali-
tative data collection point. At least two researchers
will read and independently establish coding categories
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before using an iterative approach to develop agreed
key themes, with attention to any contrasts across
groups. Stakeholder checks will be conducted where
possible to allow participant groups and key informants
to provide further comment on any resultant refine-
ments made to the intervention.
Audit Data
Analysis of these datasets will compare data from the con-
trol and intervention periods, across hospitals providing
baseline statistics of the two time periods. Descriptive and
exploratory multivariate logistic regression analyses will
be undertaken to understand health service utilisation
across the different clusters. Audit data will be linked to
birth outcomes, via above mentioned linkage processes for
control and intervention data and will be analysed using
the same methods as the secondary outcomes.
MBM trial committees
A steering committee, made up of the trial chief investiga-
tors, will meet regularly to ensure successful completion
of the trial. An independent data monitoring committee
will make recommendations to the steering committee in-
cluding early stopping due to safety concerns.
Timeline and trial end
The trial will be undertaken over 5 years including 3
years of implementation of the interventions according
to the randomisation schedule and data accrual. The
control period will commence on the 8th of August
2016 and the last day of the intervention period is the
13th May 2019. Upon the trial end date, hospitals will
provide their final routine data extract within 90 days to
allow for a complete dataset.
Discussion
Stillbirth is a common and devastating outcome with
long lasting psychosocial impact for women and families.
Many of these deaths are potentially avoidable. Maternal
perception of DFM is a marker of an at-risk pregnancy
and commonly precedes a stillbirth. However, subopti-
mal awareness by women of the importance of DFM
and/or delay in seeking health care with concerns of
DFM limits its potential. The delay is related to the lack
of appreciation of the importance of FM as a result of
inadequate information provided in busy maternity care
settings. There is support in the community and in clin-
ical practice of the need to ensure women receive better
information and support about DFM during pregnancy.
If effective, MBM offers a simple, inexpensive resource
to reduce the numbers of stillborn babies and families
suffering the distressing consequences of such a loss.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12884-019-2575-1.
Additional file 1. Statistical Analysis Plan.
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